Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Concert reported 4Q19/FY19 results yesterday. 4Q19 EPS was $(0.86) compared to FactSet consensus of $(0.79) while FY19 EPS was $(3.29) vs. consensus of $(3.22). We do not see earnings as the most important value driver for pre-commercial stage biotechs. Importantly, the company continues to make progress on the clinical development front with CTP-543, and CTP-692 – two wholly-owned assets. We continue to expect that the Phase 2 readouts from CTP-692 in schizophrenia expected by YE2020 could be an important catalyst for the shares.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
